1193 related articles for article (PubMed ID: 19636022)
41. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
43. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
Steeghs N; Gelderblom H; Roodt JO; Christensen O; Rajagopalan P; Hovens M; Putter H; Rabelink TJ; de Koning E
Clin Cancer Res; 2008 Jun; 14(11):3470-6. PubMed ID: 18519779
[TBL] [Abstract][Full Text] [Related]
44. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
[TBL] [Abstract][Full Text] [Related]
45. Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
Graham JS; Plummer R; McCoy C; Kowal K; Wiesinger H; Detjen K; Calvert H; Wiedenmann B; Cassidy J
Eur J Cancer; 2008 Oct; 44(15):2162-8. PubMed ID: 18653327
[TBL] [Abstract][Full Text] [Related]
46. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
[TBL] [Abstract][Full Text] [Related]
47. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
49. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
50. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
Moulder SL; Mahany JJ; Lush R; Rocha-Lima C; Langevin M; Ferrante KJ; Bartkowski LM; Kajiji SM; Noe DA; Paillet S; Sullivan DM
Clin Cancer Res; 2004 Nov; 10(21):7127-35. PubMed ID: 15534083
[TBL] [Abstract][Full Text] [Related]
51. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
[TBL] [Abstract][Full Text] [Related]
52. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
54. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN; Thomas AL; Molife LR; Ahmed S; Blagden S; Fong PC; Kowal K; McCoy C; Wiesinger H; Steward W; De Bono J
Cancer Chemother Pharmacol; 2009 Jul; 64(2):425-9. PubMed ID: 19280191
[TBL] [Abstract][Full Text] [Related]
55. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
56. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
58. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
59. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
[TBL] [Abstract][Full Text] [Related]
60. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
